PharmaPoint: Non-Small Cell Lung Cancer - Current and Future Players


#179433

74pages

GlobalData

$ 2995

In Stock

GlobalData has released its pharma report, PharmaPoint: Non-Small Cell Lung Cancer
Current and Future Players. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Non-Small Cell Lung Cancer Market. The report identifies and analyses the key companies shaping and driving the global Non-Small Cell Lung Cancer market. The report provides insight into the competitive Non-Small Cell Lung Cancer landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalDatas team of industry experts.

Scope

  • Investigation of current and future market competition for Non-Small Cell Lung Cancer 
  • Competitor assessment 
  • Coverage of key market players and company profiles including business description, financial overview and SWOT analysis. 
  • Strategic assessment of the Non-Small Cell Lung Cancer sector through market impact analysis, future market scenario and company analysis

Reasons to buy

  • Gain a high level view of the trends shaping and driving the Non-Small Cell Lung Cancer Market 
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition. 
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market 
  • Whats the next big thing in the global Non-Small Cell Lung Cancer market landscape? Identify, understand and capitalize
Table of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12

3 Market Outlook 13
3.1 Global Markets 13
3.1.1 Forecast 13
3.1.2 Drivers and Barriers - Global Issues 17

4 Current and Future Players 21
4.1 Overview 21
4.2 Trends in Corporate Strategy 24
4.3 Company Profiles 25
4.3.1 Roche/Genentech 25
4.3.2 Pfizer 28
4.3.3 Bristol-Myers Squibb 30
4.3.4 Eli Lilly 34
4.3.5 Boehringer Ingelheim 37
4.3.6 Novartis 39

5 Appendix 41
5.1 Bibliography 41
5.2 Abbreviations 49
5.3 Methodology 51
5.4 Forecasting Methodology 51
5.4.1 Number of NSCLC Patients Currently Seeking Treatment 51
5.4.2 Percent Drug-treated Patients 52
5.4.3 Drugs Included in Each Therapeutic Class 52
5.4.4 Launch and Patent Expiry Dates 53
5.4.5 General Pricing Assumptions 55
5.4.6 Individual Drug Assumptions 57
5.5 Physicians and Specialists Included in This Study 68
5.6 Survey of Prescribing Physicians 70
5.7 About the Authors 71
5.7.1 Authors 71
5.7.2 Global Head of Healthcare 72
5.8 About GlobalData 73
5.9 Disclaimer 73

Table 1: Global Sales Forecasts ($m) for NSCLC, 2012-2022 15
Table 2: Global NSCLC Market - Drivers and Barriers, 2012-2022 17
Table 3: Key Companies in the NSCLC Market, 2013 22
Table 4: Roche/Genentechs NSCLC Portfolio Assessment, 2013 27
Table 5: Roche/Genentech SWOT Analysis, 2013 28
Table 6: Pfizers NSCLC Portfolio Assessment, 2013 29
Table 7: Pfizer SWOT Analysis, 2013 30
Table 8: Bristol-Myers Squibbs NSCLC Portfolio Assessment, 2013 32
Table 9: BMS SWOT Analysis, 2013 33
Table 10: Eli Lillys NSCLC Portfolio Assessment, 2013 36
Table 11: Eli Lilly SWOT Analysis, 2013 36
Table 12: Boehringer Ingelheims NSCLC Portfolio Assessment, 2013 38
Table 13: BI SWOT Analysis, 2013 38
Table 14: Novartis NSCLC Portfolio Assessment, 2013 39
Table 15: Novartis SWOT Analysis, 2013 40
Table 16: Five Year Prevalence 52
Table 17: Key Launch Dates 53
Table 18: Key Patent Expiries 54
Table 19: Physicians Surveyed by Country 70
Figure 1: Global Sales for NSCLC by Region, 2012-2022 16
Figure 2: Company Portfolio Gap Analysis in NSCLC, 2012-2022 23